CochLear Ltd. Unsponsored ADR (OTCMKTS:CHEOY – Get Free Report) was the target of a large drop in short interest in the month of October. As of October 30th, there was short interest totaling 641 shares, a drop of 40.0% from the October 15th total of 1,068 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily trading volume, of 26,431 shares, the days-to-cover ratio is presently 0.0 days.
Analyst Upgrades and Downgrades
A number of equities analysts have recently commented on the company. Jefferies Financial Group downgraded CochLear from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. Canaccord Genuity Group cut shares of CochLear from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 18th. Five investment analysts have rated the stock with a Hold rating. Based on data from MarketBeat, CochLear currently has an average rating of “Hold” and an average target price of $117.00.
Check Out Our Latest Report on CHEOY
CochLear Trading Up 1.2%
About CochLear
Cochlear Limited is an Australian medical-device company that develops and supplies implantable hearing solutions for people with significant hearing loss. Its products are designed to help users access sound when conventional hearing aids may not provide sufficient benefit. The company’s offerings include cochlear implant systems and sound processors, as well as bone-conduction hearing implants and related accessories. It also provides services and support for recipients, families, and hearing-health professionals.
Featured Stories
- Five stocks we like better than CochLear
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for CochLear Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CochLear and related companies with MarketBeat.com's FREE daily email newsletter.
